Runit to participate in '2025 American Association for Cancer Research'

Medical artificial intelligence (AI) company Lunit announced on the 27th that it will present the results of a joint research with AstraZeneca at the 'American Association for Cancer Research 2025' to be held in Chicago, USA from the 25th to the 30th of next month.

The two companies have been conducting research to predict EGFR (epidermal growth factor receptor) mutations in non-small cell lung cancer (NSCLC) using AI. The presence of EGFR mutations is a key factor in determining a patient’s treatment, but there have been limitations in conducting sufficient tests due to long testing times and lack of medical resources.

Accordingly, the two companies applied their AI pathology analysis solution, 'Lunit SCOPE Genotype Predictor,' to over 12,000 non-small cell lung cancer patient data collected from medical institutions in multiple countries, including the U.S., China, and Korea, and developed a mutation prediction solution with improved performance compared to the AI model previously used for EGFR mutation testing.

As a result of the study, the mutation detection accuracy of the Runit AI solution was AUC 0.880, which is an AI performance evaluation index, significantly improving compared to 0.723 of the existing AI model.

In addition, the Runit AI solution has proven its potential for use in real clinical environments by maintaining consistent performance in studies that varied conditions, such as various tissue sample types, commercialized pathology scanners, and scan magnifications.

Seo Beom-seok, CEO of Lunit, said, “This study is the first collaborative result to be announced since the two companies agreed to jointly develop an AI pathology solution that can quickly and efficiently predict EGFR mutations in non-small cell lung cancer late last year.” He added, “Based on the research results, we will accelerate the commercialization of the AI solution for detecting EGFR mutations and expand the scope of our collaboration to mutation prediction for other types of cancer.”

• See more related articles